Key result
Cardiac contractility modulation improves quality of life, functional class, LVEF, and exercise capacity in heart failure.
Why the study?
Does cardiac contractility modulation therapy improve functional status, quality of life, and clinical outcomes in patients with heart failure?
Does cardiac contractility modulation therapy improve functional status, quality of life, and clinical outcomes in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Cardiac contractility modulation is an established device-based therapy that improves quality of life and functional status in patients with HFrEF and HFmrEF who remain symptomatic despite optimal medical therapy and are not candidates for CRT.
Cardiac contractility modulation (CCM) is a Food and Drug Administration-approved device-based therapy for patients with heart failure. The system delivers biphasic electric stimulation to the ventricular myocardium during the absolute refractory period to augment left ventricular contraction. CCM therapy promotes acute and chronic changes at the cellular level, leading to favorable remodeling throughout the myocardium. CCM improves quality of life, New York Heart Association class, left ventricular ejection fraction, peak oxygen uptake, and the composite end point of cardiovascular death and heart failure hospitalizations. This review will focus on the biological basis, indications, and evidence for CCM, as well as the future applications of this technology.
No takes yet. Share an insight, caveat, or question.
Pipilas et al. (2023) conducted a review in Heart failure. Cardiac contractility modulation (CCM) was evaluated. Cardiac contractility modulation improves quality of life, New York Heart Association class, left ventricular ejection fraction, and exercise capacity in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: